Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese Males
NCT00543946
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Healthy Japanese men age 20-45.
- BMI within 17.6 to 26.4 kg/m2 and body weight greater than or equal to 45 kg.
- Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must be able to abstain from smoking within 48 hours before study day 1 until the end of the inpatient confinement period.
- Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal,
endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
- Any surgical or medical condition that may interfere with the absorption,
distribution, metabolism, or excretion of the test article (e.g., resection of liver,
kidney, gallbladder, or gastrointestinal tract).
- Acute disease state.
- Any history of clinically important cardiac arrhythmias. Family history of long QT
syndrome, Torsades de Pointes or unexpected cardiac death.
- Any clinically important deviation from normal limits in physical examination, vital
signs, 12-lead electrocardiograms (ECGs), or clinical laboratory test results.
Creatinine levels must be less than or equal to the upper limit of normal at
screening.
- Demonstration of a positive orthostatic test at screening. The definition of a
positive test is a greater than or equal to 20 mm Hg decrease in systolic blood
pressure, greater than or equal to 10 mm Hg decrease in diastolic blood pressure, or a
greater than or equal to 30 bpm increase in pulse rate, after standing for 3 minutes.
- Positive serologic findings for human immunodeficiency virus (HIV) antigen and
antibodies, hepatitis B surface antigen (HbsAg), and/or hepatitis C virus (HCV)
antibodies.
- Positive findings of urine drug screen.
- History of any clinically important drug allergy or adverse drug reaction (e.g.,
relapsing dermatitis, drug hypersensitivity, drug allergy, hypersensitivity to
ingredient in the test articles or angioedemas)
- Use of any investigational drug within 90 days before study day 1 or prescription drug
within 30 days before study day 1.
- Consumption of any caffeine-containing products.
- Consumption of grapefruit or grapefruit-containing products within 72 hours before
study day 1 until the end of the inpatient confinement period.
- Use of any over-the-counter drugs, including herbal supplements (except for the
occasional use of vitamins less than or equal to 100% of the recommended daily
allowance), within 14 days before study day 1.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Sacramento, California
- San Francisco, California
- Washington, District of Columbia
- Orlando, Florida
- Peoria, Illinois
- Iowa City, Iowa
- Worcester, Massachusetts
- Ann Arbor, Michigan
- Lansing, Michigan
- Southfield, Michigan
- Minneapolis, Minnesota
- Newark, New Jersey
- Winston-Salem, North Carolina
- Cleveland, Ohio
- Cleveland, Ohio
- Hershey, Pennsylvania
- Wynnewood, Pennsylvania
- Falls Church, Virginia
- Norfolk, Virginia
- Edmonton, Alberta
- Vancouver, British Columbia
- Victoria, British Columbia
- St-Johnâ s, Newfoundland and Labrador
- Halifax, Nova Scotia
- London, Ontario
- Newmarket, Ontario
- Toronto, Ontario
- Fleurimont, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Sainte-Foy, Quebec
- Sherbrooke, Quebec
- Philadelphia, Pennsylvania
- San Francisco, California
- Washington, District of Columbia
- Hershey, Pennsylvania
- Ottawa, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Montreal, Quebec
- Aalst,
- Antwerpen,
- Brugge,
- Edegem,
- Gent,
- Hasselt,
- Leuven,
- Athens,
- Crete,
- Rio Patra,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese Males | |||
Official Title ICMJE | Ascending Single Dose Study of The Safety, Tolerability, Pharmacokinetics, of GAP-134 Administered Intravenously as a 24-Hour Infusion to Healthy Japanese Male Subjects | |||
Brief Summary | This is a study of GAP-134, an antiarrhythmic di-peptide. This study will provide an initial assessment of the safety, tolerability, and pharmacokinetics (PK) of GAP-134 after administration of ascending single intravenous (IV) doses to healthy Japanese male subjects. | |||
Detailed Description | Atrial Fibrillation (AF) is the most commonly occurring sustained arrhythmia in clinical practice. AF is a serious disorder associated with an increased risk of stroke, morbidity and mortality, and the number of patients is estimated to double within the next 4 decades. The currently available antiarrhythmic drugs have limited efficacy and are associated with serious side effects of which potentially lethal ventricular proarrhythmias are one of the major concerns. Thus, there is a large unmet clinical need for efficacious and safe antiarrhythmic drugs for the treatment of AF. The classical orientation of antiarrhythmic therapy has been to modulate cardiac ion channels (sodium, potassium or calcium) or the autonomic nervous system. However, numerous experimental and clinical studies have suggested that cardiac conduction slowing and impaired gap junction intercellular communication (GJIC) are important in the pathogenesis of cardiac arrhythmias, including AF. General conduction slowing or the presence of small islands of intra-atrial conduction block resulting from a decreased gap junction conductance, altered gap junction expression and heterogeneous spatial distribution of gap junctions may provide turning points for the multiple waves, and thereby promote re-entry of impulses. In recognition of this, several authors have proposed gap junction modulation as a potential new target in the treatment of AF. GAP-134 is an antiarrhythmic dipeptide that has demonstrated in vitro and in vivo efficacy in mouse and dog models of arrhythmia. GAP-134 has no apparent proarrhythmic activity or hemodynamic compromise and does not show any significant binding in a panel of >60 different receptors and ion channels. If determined to be safe and effective the indication sought for GAP-134 will be the prevention of post operative atrial fibrillation. | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 1 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Single Group Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Prevention | |||
Condition ICMJE | Arrhythmia | |||
Intervention ICMJE | Drug: GAP-134
24-Hour IV infusion, SAD | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 56 | |||
Original Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | March 2008 | |||
Actual Primary Completion Date | March 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria
Exclusion Criteria
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 20 Years to 45 Years (Adult) | |||
Accepts Healthy Volunteers ICMJE | Yes | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Japan | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00543946 | |||
Other Study ID Numbers ICMJE | 3205K2-1002 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Study Sponsor ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Verification Date | September 2018 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |